Tom Leary, head of Government Relations at HIMSS, discusses potential changes in healthcare policy under the Biden administration, including regulations for interoperability and data sharing. HIMSS also focuses on AI, cybersecurity, and regulation transparency. The organization pushes for continued telehealth and remote patient monitoring post-COVID-19. Industry stakeholders expect different impacts under a Biden presidency, including pharmaceutical companies and Medicare Advantage insurers. Abortion rights supporters express concerns about reproductive freedom under the new administration.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
